Menu

Duchenne pioneer says FDA rejection of Sarepta’s drug ‘would be a travesty’

Don Seiffert

Lou Kunkel (Boston Children’s) participated in an interview about two drugs pending approval by the Food and Drug Administration.

Read the full article